TFAP2B and neoplasm: In NSCLC, both TFAP2A and TFAP2B are implicated in promoting tumor-induced angiogenesis via platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR) and TGF-β signaling pathways [65, 66].